Sánchez Guillermo, Castro Carlos
Department of Research, Soluciones Integrales para la Investigación y la Educación en Salud (SIIES), Bogotá, Colombia.
Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.
Int Arch Otorhinolaryngol. 2019 Jul;23(3):e325-e330. doi: 10.1055/s-0039-1688968. Epub 2019 May 28.
Oral antihistamines and intranasal corticosteroids have been shown to be effective and safe for the treatment of allergic rhinitis; however, the evidence suggests a level of superiority of corticosteroids, so they should be preferred over the former. To know the prescription profile of two second generation antihistamines (cetirizine and levocetirizine) and two nasal corticosteroids (mometasone and furoate-ciclesonide) in a cohort of patients with allergic rhinitis, and to compare the clinical outcomes obtained. A cohort study was carried including patients with allergic rhinitis treated with cetirizine, levocetirizine, mometasone furoate or ciclesonide. The improvement was evaluated with the total nasal symptoms score (TNSS). This scale yields results between 0 and 12. Zero indicates absence of symptoms. A total of 314 patients completed 12 weeks of follow-up. Seventy-five percent were treated with antihistamines, 20% with corticosteroids, and 5% with a combination of the above. The TNSS median for corticosteroid was 2.5 points; for antihistamines, its was 5 points, and for combination, it was 4 points. We found differences between corticosteroids and antihistamines. The prescription percentage of second generation oral antihistamines is higher than that of intranasal corticosteroids. However, patients with allergic rhinitis treated with the second option obtained better control of symptoms.
口服抗组胺药和鼻用皮质类固醇已被证明对过敏性鼻炎的治疗有效且安全;然而,证据表明皮质类固醇具有一定程度的优越性,因此应优先于前者使用。 为了解一组过敏性鼻炎患者中两种第二代抗组胺药(西替利嗪和左西替利嗪)以及两种鼻用皮质类固醇(糠酸莫米松和环索奈德)的处方情况,并比较所获得的临床疗效。 进行了一项队列研究,纳入了接受西替利嗪、左西替利嗪、糠酸莫米松或环索奈德治疗的过敏性鼻炎患者。使用总鼻症状评分(TNSS)评估改善情况。该量表的结果在0至12分之间。零分表示无症状。 共有314名患者完成了12周的随访。75%的患者接受抗组胺药治疗,20%接受皮质类固醇治疗,5%接受上述药物联合治疗。皮质类固醇组的TNSS中位数为2.5分;抗组胺药组为5分,联合治疗组为4分。我们发现皮质类固醇和抗组胺药之间存在差异。 第二代口服抗组胺药的处方百分比高于鼻用皮质类固醇。然而,接受第二种治疗方法的过敏性鼻炎患者症状控制得更好。